B
Bull
Bull · 25%EBS
$7.49
Precio del escenario
$6.220
+0.123 (+1.97%)Al cierre
Loading chart…
- High
- 6.285
- Open
- 6.160
- VWAP
- 6.17
- Vol
- 972.44K
- Mkt Cap
- 365.76M
- Low
- 5.995
- Amount
- 6.00M
- EV/EBITDA, TTM
- 2.54
Emergent BioSolutions, Inc. is a life sciences company. It is focused on providing preparedness and response solutions addressing accidental, deliberate and naturally occurring public health threats. Its solutions include a product portfolio, a product development portfolio, and a contract development and manufacturing services portfolio. Its segments include Commercial Products, MCM Products, and Services segment. Its Commercial Product segment consists of NARCAN Nasal Spray. Its MCM Products segment consists of Anthrax MCM products, Smallpox MCM products and Other Products. Its Services segment consists of its Bioservices portfolio. NARCAN (naloxone HCl) Nasal Spray, an intranasal formulation of naloxone, is developed for the emergency treatment of known or suspected opioid overdose as manifested by respiratory and central nervous system depression. Its Bioservices consist of development services, bulk drug substance manufacturing, fill, finish, and packaging of final drug products.
AI analysis of Emergent BioSolutions Inc (EBS)
sellEmergent BioSolutions Inc (EBS) is not a good buy right now due to a significant net loss of $180.2 million reported in Q2 2026, alongside a current price of $5.91 that is well below its 200-day moving average of $9.14. Additionally, the RSI is at 72.702, indicating the stock is overbought, and insider selling has increased by 140.86%, suggesting a lack of confidence from those within the company. The main risk is the company's ongoing transition phase and competition in the naloxone market, which has led to lowered earnings expectations and price target cuts from analysts.
Analyst Ratings (6)
+141.16% upside
Buy
5 Buy
1 Hold
0 Sell
Current: 6.22
Mínimo
15.00
Promedio
15.00
Máximo
15.00
JPMorgan
Underweight
—
2026-08-21
JPMorgan
2026-08-21
Precio objetivo
—
Underweight
H.C. Wainwright
Buy
$10
2026-08-10
H.C. Wainwright
2026-08-10
Precio objetivo
$10
Buy
H.C. Wainwright
Buy
$12
2026-03-09
H.C. Wainwright
2026-03-09
Precio objetivo
$12
Buy
JPMorgan
Overweight
—
2025-12-02
JPMorgan
2025-12-02
Precio objetivo
—
Overweight
Barclays
Overweight
—
2025-12-02
Barclays
2025-12-02
Precio objetivo
—
Overweight
Métricas de valoración
The current forward P/E ratio for Emergent BioSolutions Inc (EBS) is 2.08, compared to its 5-year average forward P/E of 12.81.
Alphio AI Price Scenarios for EBS
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Cronología de eventos
Noticias
7.008-27PRnewswireEmergent BioSolutions Under Investigation for Securities Fraud
7.008-19NewsfilterEmergent BioSolutions Under Investigation for Securities Violations
- 7.008-17Newsfilter
Emergent BioSolutions Under Investigation for Securities Violations
7.008-17PRnewswireEmergent BioSolutions Faces Securities Investigation After Q2 Losses
2.008-11stocktwitsTTD, PZZA, and EBS Stocks Continue to Decline
EBS FAQ — answered by Alphio AI
Emergent BioSolutions, Inc. is a life sciences company. It is focused on providing preparedness and response solutions addressing accidental, deliberate and naturally occurring public health threats. Its solutions include a product portfolio, a product development portfolio, and a contract development and manufacturing services portfolio. Its segments include Commercial Products, MCM Products, and Services segment. Its Commercial Product segment consists of NARCAN Nasal Spray. Its MCM Products segment consists of Anthrax MCM products, Smallpox MCM products and Other Products. Its Services segment consists of its Bioservices portfolio. NARCAN (naloxone HCl) Nasal Spray, an intranasal formulation of naloxone, is developed for the emergency treatment of known or suspected opioid overdose as manifested by respiratory and central nervous system depression. Its Bioservices consist of development services, bulk drug substance manufacturing, fill, finish, and packaging of final drug products. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Emergent BioSolutions Inc (EBS) is not a good buy right now due to a significant net loss of $180.2 million reported in Q2 2026, alongside a current price of $5.91 that is well below its 200-day moving average of $9.14. Additionally, the RSI is at 72.702, indicating the stock is overbought, and insider selling has increased by 140.86%, suggesting a lack of confidence from those within the company. The main risk is the company's ongoing transition phase and competition in the naloxone market, which has led to lowered earnings expectations and price target cuts from analysts.
6 analysts cover EBS: 5 rate it Buy, 1 Hold and 0 Sell. The average price target is 15.00.
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.